It is time to change thrombosis risk assessment for PV and ET?
Author:
Publisher
Elsevier BV
Subject
Clinical Biochemistry,Oncology
Reference56 articles.
1. Proposals and rationale for revision of the world health organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel;Tefferi;Blood,2007
2. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies;Passamonti;Oncotarget,2011
3. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2;Nangalia;N Engl J Med,2013
4. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons;Tefferi;Leukemia,2014
5. JAK inhibitor in CALR-mutant myelofibrosis;Passamonti;N Engl J Med,2014
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Vascular target organ damage in patients with Philadelphia negative myeloproliferative syndrome: A propensity score analysis;Medicina Clínica (English Edition);2022-06
2. Vascular target organ damage in patients with Philadelphia negative myeloproliferative syndrome: A propensity score analysis;Medicina Clínica;2021-08
3. Bleeding and Thrombosis;Oncologic Emergency Medicine;2021
4. Antiphospholipid syndrome – a life threatening condition;Revista Romana de Medicina de Laborator;2019-07-01
5. Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia;Leukemia Research;2018-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3